Charles River Laboratories International, Inc.
CRL · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $7,373 | $7,883 | $9,440 |
| - Cash | $208 | $183 | $229 | $195 |
| + Debt | $2,629 | $2,786 | $2,986 | $2,724 |
| Enterprise Value | – | $9,976 | $10,639 | $11,969 |
| Revenue | $1,005 | $1,032 | $984 | $1,003 |
| % Growth | -2.6% | 4.9% | -1.8% | – |
| Gross Profit | $339 | $357 | $318 | $284 |
| % Margin | 33.7% | 34.6% | 32.3% | 28.4% |
| EBITDA | $198 | $221 | $184 | -$86 |
| % Margin | 19.7% | 21.4% | 18.7% | -8.6% |
| Net Income | $54 | $52 | $25 | -$216 |
| % Margin | 5.4% | 5.1% | 2.6% | -21.5% |
| EPS Diluted | 1.1 | 1.06 | 0.5 | -4.22 |
| % Growth | 3.8% | 112% | 111.8% | – |
| Operating Cash Flow | $214 | $205 | $172 | $159 |
| Capital Expenditures | -$36 | -$35 | -$59 | -$76 |
| Free Cash Flow | $178 | $169 | $112 | $84 |